schliessen

Filtern

 

Bibliotheken

吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察 - Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer

目的探讨吉西他滨联合卡培他滨治疗转移性三阴乳腺癌的效果。方法对32例转移性三阴乳腺癌予吉西他滨联合卡培他滨方案化疗:吉西他滨1g/m2静脉滴注,d1、8;卡培他滨1250mg/m2口服、2/d,d1~14,3周为1个周期。2个周期后初步评价疗效,如肿瘤进展更换方案,有效者继续应用至少2个周期,共用4个周期后评价疗效及毒性反应。结果本组完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)12例,进展(PD)6例,总有效(CR+PR)率43.8%,临床获益(CBR)率为62.5%(20/32),主毒性反应为骨髓抑制及手足综合征。结论吉西他滨联合卡培他滨治疗转移性三阴乳腺癌近期效果满意,毒性反... Full description

Journal Title: 解放军医药杂志 - Medical Journal of Beijing Military Region 2013, Issue 01, pp.36-38
Main Author: 赵增虎
Other Authors: 刘俊堂 , 丁瑞亮 , 王小燕 , ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
Format: Electronic Article Electronic Article
Language:
Subjects:
Quelle: 维普数据 (Chongqing VIP Information Co.)
ID: ISSN: 2095-140X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cqvip44585817
title: 吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察 - Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer
format: Article
creator:
  • 赵增虎
  • 刘俊堂
  • 丁瑞亮
  • 王小燕
  • ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
subjects:
  • 吉西他滨
  • 卡培他滨
  • 转移性三阴乳腺癌
  • 治疗结果
  • Gemeitabine
  • Capeeitabine
  • Metastatic Triple-Negative Breast Cancer
  • Treatment Outcome
ispartof: 解放军医药杂志 - Medical Journal of Beijing Military Region, 2013, Issue 01, pp.36-38
description: 目的探讨吉西他滨联合卡培他滨治疗转移性三阴乳腺癌的效果。方法对32例转移性三阴乳腺癌予吉西他滨联合卡培他滨方案化疗:吉西他滨1g/m2静脉滴注,d1、8;卡培他滨1250mg/m2口服、2/d,d1~14,3周为1个周期。2个周期后初步评价疗效,如肿瘤进展更换方案,有效者继续应用至少2个周期,共用4个周期后评价疗效及毒性反应。结果本组完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)12例,进展(PD)6例,总有效(CR+PR)率43.8%,临床获益(CBR)率为62.5%(20/32),主毒性反应为骨髓抑制及手足综合征。结论吉西他滨联合卡培他滨治疗转移性三阴乳腺癌近期效果满意,毒性反应低,可作为二线化疗方案。
language:
source: 维普数据 (Chongqing VIP Information Co.)
identifier: ISSN: 2095-140X
fulltext: no_fulltext
issn:
  • 2095-140X
  • 2095140X
url: Link


@attributes
ID263397790
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid44585817
sourceidcqvip
recordidTN_cqvip44585817
sourceformatDC
sourcesystemPC
display
typearticle
title吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察 - Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer
creator赵增虎 ; 刘俊堂 ; 丁瑞亮 ; 王小燕 ; ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
ispartof解放军医药杂志 - Medical Journal of Beijing Military Region, 2013, Issue 01, pp.36-38
identifierISSN: 2095-140X
subject吉西他滨 ; 卡培他滨 ; 转移性三阴乳腺癌 ; 治疗结果 ; Gemeitabine; Capeeitabine; Metastatic Triple-Negative Breast Cancer; Treatment Outcome
description
0目的探讨吉西他滨联合卡培他滨治疗转移性三阴乳腺癌的效果。方法对32例转移性三阴乳腺癌予吉西他滨联合卡培他滨方案化疗:吉西他滨1g/m2静脉滴注,d1、8;卡培他滨1250mg/m2口服、2/d,d1~14,3周为1个周期。2个周期后初步评价疗效,如肿瘤进展更换方案,有效者继续应用至少2个周期,共用4个周期后评价疗效及毒性反应。结果本组完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)12例,进展(PD)6例,总有效(CR+PR)率43.8%,临床获益(CBR)率为62.5%(20/32),主毒性反应为骨髓抑制及手足综合征。结论吉西他滨联合卡培他滨治疗转移性三阴乳腺癌近期效果满意,毒性反应低,可作为二线化疗方案。
1Objective To explore the effect of Gemcitabine combined with Capeeitabine in treatment of metastat- ic triple-negative breast cancer. Methods The 32 patients with metastatic triple-negative breast cancer were treated with Gemeitabine iv gtt 1g/m2 , d 1,8, and Capeeitabine po 1250 mg/m2 , 2/d , d 1-14. Three weeks was one cycle. Preliminary assessment of efficacy were preformed at two cycles after chemotherapy, program was changed if there was tumor progression, while effective patients were continued at least another two cycles. The efficacy and toxicity were evaluated at 4 cycles after treatment. Results There were 1 patient with complete response, 13 patients with partial re- sponse, 12 patients with stable disease and 6 patients with progression disease. The total effective rate was 43.8% ( 14/ 32). Clinical benefit rate (CBR) was 62.5% (20/32). The main toxic reactions were myelosuppression and hand-foot syndrome. Conclusion The method of Gemeitabine combined with Capeeitabine may be used as second-line therapy program in treatment of metastatic triple-negative breast cancer.
relation作者单位: 解放军251医院肿瘤科,河北张家口075000
source维普数据 (Chongqing VIP Information Co.)
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Uhttp://image.cqvip.com/vip1000/qk/83734B/83734B.jpg
search
creatorcontrib
0赵增虎
1刘俊堂
2丁瑞亮
3王小燕
4ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
5解放军251医院肿瘤科,河北张家口075000
title
0吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察
1Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer
description
0目的探讨吉西他滨联合卡培他滨治疗转移性三阴乳腺癌的效果。方法对32例转移性三阴乳腺癌予吉西他滨联合卡培他滨方案化疗:吉西他滨1g/m2静脉滴注,d1、8;卡培他滨1250mg/m2口服、2/d,d1~14,3周为1个周期。2个周期后初步评价疗效,如肿瘤进展更换方案,有效者继续应用至少2个周期,共用4个周期后评价疗效及毒性反应。结果本组完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)12例,进展(PD)6例,总有效(CR+PR)率43.8%,临床获益(CBR)率为62.5%(20/32),主毒性反应为骨髓抑制及手足综合征。结论吉西他滨联合卡培他滨治疗转移性三阴乳腺癌近期效果满意,毒性反应低,可作为二线化疗方案。
1Objective To explore the effect of Gemcitabine combined with Capeeitabine in treatment of metastat- ic triple-negative breast cancer. Methods The 32 patients with metastatic triple-negative breast cancer were treated with Gemeitabine iv gtt 1g/m2 , d 1,8, and Capeeitabine po 1250 mg/m2 , 2/d , d 1-14. Three weeks was one cycle. Preliminary assessment of efficacy were preformed at two cycles after chemotherapy, program was changed if there was tumor progression, while effective patients were continued at least another two cycles. The efficacy and toxicity were evaluated at 4 cycles after treatment. Results There were 1 patient with complete response, 13 patients with partial re- sponse, 12 patients with stable disease and 6 patients with progression disease. The total effective rate was 43.8% ( 14/ 32). Clinical benefit rate (CBR) was 62.5% (20/32). The main toxic reactions were myelosuppression and hand-foot syndrome. Conclusion The method of Gemeitabine combined with Capeeitabine may be used as second-line therapy program in treatment of metastatic triple-negative breast cancer.
subject
0吉西他滨
1卡培他滨
2转移性三阴乳腺癌
3治疗结果
4Gemeitabine
5Capeeitabine
6Metastatic Triple-Negative Breast Cancer
7Treatment Outcome
general
0chinese
1维普数据 (Chongqing VIP Information Co.)
sourceidcqvip
recordidcqvip44585817
issn
02095-140X
12095140X
rsrctypearticle
creationdate2013
startdate20130101
enddate20131231
addtitle
0解放军医药杂志
1Medical Journal of Beijing Military Region
searchscopecqvip
scopecqvip
lsr01
0解放军251医院肿瘤科,河北张家口075000
1ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan (Department of Oneology, 251 Hospital of PLA, Zhangjiakou, Hebei 075000, China)
citationpf 36 pt 38 issue 01
sort
title吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察 - Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer
author赵增虎 ; 刘俊堂 ; 丁瑞亮 ; 王小燕 ; ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
creationdate20130000
lso0120130000
facets
frbrgroupid6120714939770380987
frbrtype6
creationdate2013
topic
0吉西他滨
1卡培他滨
2转移性三阴乳腺癌
3治疗结果
4Gemeitabine; Capeeitabine; Metastatic Triple-Negative Breast Cancer; Treatment Outcome
collection维普资讯 (Chongqing VIP Information Co.)
prefilterarticles
rsrctypearticles
creatorcontrib
0赵增虎
1刘俊堂
2丁瑞亮
3王小燕
4ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
jtitle
0解放军医药杂志
1Medical Journal of Beijing Military Region
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0赵增虎
1刘俊堂
2丁瑞亮
3王小燕
4ZHAO Zeng-hu, LIU Jun-tang, DING Rui-liang, WANG Xiao-yan
atitle吉西他滨联合卡培他滨治疗转移性三阴乳腺癌32例临床观察 - Clinical Observation of Gemcitabine Combined with Capecitabine in the Treatment of 32 Patients with Metastatic Triple-Negative Breast Cancer
jtitle解放军医药杂志
date2013
risdate2013
issue01
part83734B
spage36
epage38
issn2095-140X
coden83734B
formatjournal
genrearticle
ristypeJOUR
abstract
0目的探讨吉西他滨联合卡培他滨治疗转移性三阴乳腺癌的效果。方法对32例转移性三阴乳腺癌予吉西他滨联合卡培他滨方案化疗:吉西他滨1g/m2静脉滴注,d1、8;卡培他滨1250mg/m2口服、2/d,d1~14,3周为1个周期。2个周期后初步评价疗效,如肿瘤进展更换方案,有效者继续应用至少2个周期,共用4个周期后评价疗效及毒性反应。结果本组完全缓解(CR)1例,部分缓解(PR)13例,稳定(SD)12例,进展(PD)6例,总有效(CR+PR)率43.8%,临床获益(CBR)率为62.5%(20/32),主毒性反应为骨髓抑制及手足综合征。结论吉西他滨联合卡培他滨治疗转移性三阴乳腺癌近期效果满意,毒性反应低,可作为二线化疗方案。
1Objective To explore the effect of Gemcitabine combined with Capeeitabine in treatment of metastat- ic triple-negative breast cancer. Methods The 32 patients with metastatic triple-negative breast cancer were treated with Gemeitabine iv gtt 1g/m2 , d 1,8, and Capeeitabine po 1250 mg/m2 , 2/d , d 1-14. Three weeks was one cycle. Preliminary assessment of efficacy were preformed at two cycles after chemotherapy, program was changed if there was tumor progression, while effective patients were continued at least another two cycles. The efficacy and toxicity were evaluated at 4 cycles after treatment. Results There were 1 patient with complete response, 13 patients with partial re- sponse, 12 patients with stable disease and 6 patients with progression disease. The total effective rate was 43.8% ( 14/ 32). Clinical benefit rate (CBR) was 62.5% (20/32). The main toxic reactions were myelosuppression and hand-foot syndrome. Conclusion The method of Gemeitabine combined with Capeeitabine may be used as second-line therapy program in treatment of metastatic triple-negative breast cancer.
lad0183734B